Bajaj Healthcare seeks compulsory license for Covid-19 drug On 28 June, drugmaker Bajaj Healthcare requested the Indian patent office to grant a compulsory licence to make Baricitinib, an Eli Lilly drug, which has shown promise in treating Covid-19.
Bajaj Healthcare, which makes Covid drugs like favipiravir and ivermectin, has sought permission to make both the active pharmaceutical ingredient (API) and the formulation of Baricitinib.
The company approached Eli Lilly on two occasions, to sign the voluntary licence for manufacturing and supply of Covid-19 drug Baricitinib. Company’s board approves listing on NSE On Monday, Bajaj Healthcare informed the exchanges about listing of equity shares on National Stock Exchange (NSE).